The Children’s Lipid Centre at KKH is Singapore’s first dedicated clinic for the management of familial hypercholesterolaemia (FH) in children. Find out more.
The KKH Children's Lipid Centre
KK Women’s and Children’s Hospital (KKH) has opened the new Children’s Lipid Centre, Singapore’s first dedicated clinic for the management of familial hypercholesterolaemia (FH) in children. Part of the Metabolic Health Programme, under the KKH-led SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI), the Centre will proactively identify and manage FH in early childhood.
WHAT IS FAMILIAL HYPERCHOLESTEROLAEMIA?
FH is an inherited disorder. Due to mutations in genes involved in the metabolism of cholesterol, the affected child is born with abnormal lipid levels which are characterised by very high levels of low-density lipoprotein cholesterol (LDL-C), commonly known as ‘bad cholesterol’.
This leads to the development of atherosclerosis, a build-up of fatty deposits that causes blockages and narrowing of the blood vessels, and subsequently, cardiovascular diseases.
UNIQUE CONSIDERATIONS OF FH MANAGEMENT IN CHILDREN
FH in childhood can manifest more severely and require targeted diagnosis and aggressive treatment, unlike FH in adults which can be managed by statins and lipid-lowering drugs.
Of greater concern is the fact that FH in childhood can also be insidious and stay silent until cholesterol levels are actually measured. Being genetic, FH cannot be addressed by dietary and lifestyle changes alone.
As the risk of atherosclerosis is cumulative and starts early in life, early detection for children at risk of this genetic condition is crucial. For instance, the first two years of life is key to the diagnosis of Homozygous FH (HoFH), a more severe form of FH which is inherited from both parents.
PREVALENCE IN SINGAPORE
The prevalence of FH in Singapore is around one in 1401 or over 35,000 persons, including 4,000 children and adolescents. Yet over 90% of FH cases in Singapore remain undiagnosed or do not receive timely treatment, especially in children and adolescents.
PRESENTATION
Children with untreated FH typically have LDL-C levels of at least 3.5 mmol/L.
Those with LDL-C over 4.0 mmol/L would require early LDL-C lowering treatment since they remain asymptomatic while the silent effects on the vascular endothelium build over time.
The optimal LDL-C for children aged two to 18 years is less than 3.5 mmol/L.
Precision Population Health Through Screening and Early Detection
Early screening for at-risk children
The Children’s Lipid Centre encourages early screening for at-risk children to limit the risks of lifelong cholesterol build-up and related diseases.
They include children whose immediate family members have FH, or a history of developing cardiovascular disease earlier in life. For women, it would be before 65 years, and for men, before 55 years.
Importantly, a child’s diagnosis can often lead to identifying and treating an affected parent or family member.
Tailored management
In managing children diagnosed with FH, the Centre will focus on individual characteristics and genomics to administer tailored therapy, at the right time, for each affected child.
The KKH Children’s Lipid Centre is expected to screen and manage around 120 children annually.
Reducing the cardiovascular disease burden FH in adulthood carries a 50% chance of the condition being passed down to the next generation.
Individuals with FH are potential time bombs, unaware of their condition until it manifests into serious health issues. For those affected, this can be addressed with early screening and intervention. These are also the first steps toward realising a future of a population free from cardiovascular disease.
General practitioners are invited to refer at-risk patients for screening via this link.
|
- ‘Analysis of clinically relevant variants from ancestrally diverse Asian genomes’, Chan SH, SG10K_Heatlh Consortium, et al, Nature Communications (2022).
